News and Comments

The FDA Approval of Exelixis Drug Cabometix™ Is Indeed Great News

  Tuesday, April 26, 2016

Congratulation.   More...

One Year Accomplishments Vs. One Cent Missed in Agenus Financial Report

  Thursday, March 03, 2016

Agenus (AGEN) is a project in the making since the firm has decided to play an integral part in immuno-oncology, doing everything possible towards building checkpoint modulator antibodies, in addition to its protective and therapeutic vaccines.    More...

Exelixis: Great News Towards Great Changes

  Tuesday, March 01, 2016

Exelixis’ (EXEL) quarterly results beat analysts’ expectations, which was the least of our concerns. The details of the firm’s actions during the past year, however, confirmed our conviction that the recently approved products will be taken care of responsibly by the firm that created them and believed in them against all pessimistic opinions.  More...

Exeixis Will Begin Reaping the Fruits

  Tuesday, November 10, 2015

 More...

The Stream of Exelixis Good News is Real

  Thursday, October 22, 2015


 More...

Why Switzerland Approval of Exelixis and Roche Drug Combination for melanoma is a Big Deal?

  Thursday, August 27, 2015

 More...

EXELEXIS: The Importance Of The Public Offering. XOMA: What Should We Do Now?

  Thursday, July 23, 2015

Why the financing through a secondary public offering was a must for Exelixis?  More...

EXELIXIS: TIME FOR TRANSFORMATION. THE BEST IS YET TO COME

  Wednesday, July 16, 2014

We stayed with Exelixis (EXEL) In spite of the negative articles that made this firm look as if planting seeds in the ocean. Investors acted as if condemning the firm’s efforts, its small molecule drug design technology and its investigational oncology products. We remained fans in spite of the complete paralysis of the stock for a long time. We always believed that all the negatives about this firm measure little compared to its positives. More...

Circumstances That Encourage Picking Specific Biotech Stocks

  Tuesday, January 10, 2012

Picking biotech stocks for short-term and long-term investment could be a good practice if investors know what to pick. In most cases, picking biotech stocks that have no near-term catalysts could be disappointing, leading investors to wait and wait, then get bored, and sell their shares at a great loss. To pick firms in early- or mid-phase development the firms should have very advanced technologies and product pipelines with strong evidence of promise that they are the envy of rich pharmaceutical firms. The large-pocketed drug developers usually desire what they need and buy what they desire. Most are currently in dire need of breakthrough products, as the patent lives of many of their bestsellers are expiring. Investors must be aware of the fact that stocks of development-stage firms’ are destined to fall after each and every quarterly financial results announcement, as they have no revenues or incomes. They also fall after shareholders get disappointed in the negative performances of their stocks, hence, trash them. Compensation can come early, however, in the event of takeovers, alliances that pay huge upfront payments, or the announcement of stunningly positive clinical trial results of products that deal with life-threatening diseases with large markets. Focused investors may be able to catch big fish in situations exemplified by the following three circumstances: More...

BIOTECHNOLOGY PROMISES A HUGE GROWTH

  Wednesday, December 21, 2011

EXELIXIS’ (EXEL) advanced PI3K-delta research and development preclinical program attracted Merck, known as MSD outside of the United States and Canada. “PI3K-delta is therapeutic target that academic researchers and the drug industry are racing to develop therapeutic antagonists for both inflammatory diseases and cancer. To get to Exelixis program, Merck agreed to pay $12 million in upfront payment in addition to potential milestone payments for multiple indications of up to $239 million and royalties on net-sales of products that would emerge from the agreement. Merck will also pay Exelixis royalties on any compounds that would emerge from Exelixis’ PI3K-delta program or from certain compounds that arise from Merck’s internal discovery efforts targeting PI3K-delta during a certain period. More...


Recent Postings


Archive


Tags

Zerenex GUARDIAN HEALTH Trastuzumab-DM1 Pluristem (PSTI) Auspex (ASPX) Onyx (ONXX) HALOZYME (HALO) Biogen Idec (BIIB) Herceptin galapagos (GLPG) Alnylam (ALNY) Illumina (ILMN) Amgen (AMGN) Xoma (XOMA) Sanofi (SNA) REGULUS (RGLS) KITE (KITE) Sequenom (SQNM) AERIE PHARMACEUTICALS Micromet (MITI) Ridaforolimus Aimmune Therapeutics (AIMT) ABBVIE (ABBV) Merck (MRK) Agenus (AGEN Galena (GALE) Velcade (bortezomib) Intercept (ICPT) Intermune (ITMN) NANTKWEST (NK) Intrexon (XON) Biocryst (BCRX) Dynavax (DVAX) Multiple Myeloma Revlimid (lenolidamide) BIOMARIN (BMRN) Rapamune Seattle Genetics (SGEN) Genentech C4 Therapeutics SUNESIS PHARMACEUTICALS (SNSS) ACADIA (ACAD) SYNTA (SNTA) Human Longevity (HLI) Agenus (AGEN) Array Pharmaceuticals (ARRY) Anadys (ANDS) KERYX (KERX) Mirati Therapeutics (MRTX) Sarepta (SRPT) Prosensa (RNA) Abbott Laboratories (ABT) Bristol-Myers Squibb (BMY) ARCA (ABIO) Roche (RHHBY) IDERA (IDRA) Ziofpharm (ZIOP) Vitae Pharmaceuticals (VTAE) ISIS (ISIS) Valeant Pharmaceuticals International (VRX) NEKTAR (NKTR)) ADVENTRIX (ANX) Sanofi-Aventis (SAN) Sangamo (SGMO) Endometrial Cancer OSI (OSIP) Vertex (VRTX) Elan (ELN) CompuGen (CGEN) VANDA (VNDA) Human Genome Sciences (HGSI) Cytokinetics (CYTK) Roche (ROCHE) TOKAI (TKAOI) JUNO (JUNO) Regeneron (REGN) Exelixis (EXEL) Inovio (INO) GlaxoSmithKline (GSK) Ionis (IONS) Theravance (THRX) Telaprevir Theravance Bio Pharma (TBPH) Gilead (GILD) Jazz Pharmaceuticals (JAZZ) SERES THERAPEUTICS (MCRB) Dendreon (DNDN) ImmunoGen (IMGN) ZALTRAP™ Anacor (ANAC) Idenix (IDIX) Alder Biopharmaceuticals (ALDR) Prolor Biotech (PBTH) Ariad (ARIA) Incyte (INCY) Tysabri Sanofi (SNY) Benlysta (belimumab)